Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for ...

A consensus statement from the Society for Perioperative Assessment and Quality Improvement recommends patients should ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

The first reason is because the mechanism of action [MOA] of using a GLP-1 Receptor ... short amount of 12-weeks already proved that its GLP-1 RA MET-097i already attained a mean placebo adjusted ...

The researchers found that the incidence of VTE was 11.0 versus 12.9 events per 1,000 patient-years in the GLP-1 RA and DPP-4 inhibitor cohorts, respectively, with an 18 percent lower risk for VTE ...

The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0% for GLP-1 RA users and 10.7% for nonusers.

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity. HealthDay News — From 2010 to 2023, there was an ...

glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for cirrhosis and for cirrhosis complications and mortality, according to a study published online Sept.

Combination therapy with GLP-1 RA and thiazolidinedione significantly reduces all-cause mortality and cardiovascular mortality in type 2 diabetes patients. The study found an increased risk of ...

Twelve GLP-1 RA medications were studied, 3 that are FDA-approved (liraglutide, semaglutide, and tirzepatide) and 9 that are not yet approved for weight management. Treatment periods lasted from ...

Get Instant Summarized Text (Gist) GLP-1 receptor agonists are safe and effective for weight loss and glycemic control in adults with severe mental illness, including those on psychotropic medications ...

The researchers found that the incidence of VTE was 11.0 versus 12.9 events per 1,000 patient-years in the GLP-1 RA and DPP-4 inhibitor cohorts, respectively, with an 18% lower risk for VTE for ...